News of medicine
- Issue: Vol 30, No 12 (2023)
- Pages: 6-10
- Section: News of Medicine
- URL: https://journals.eco-vector.com/2073-4034/article/view/626067
- ID: 626067
Cite item
Open Access
Access granted
Abstract
Type 2 diabetes mellitus (T2DM) is a serious disease
Keywords
Full Text
References
- Sattar N.; McLaren J.; Kristensen S.L.; et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333–39.
- Verma S.; McMurray J.J.V.; Cherney D.Z.I. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol. 2017;2(9):939–40.
- Shin S.J.; Chung S.; Kim S.J.; et al. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor; Dapagliflozin; on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. PLoS One. 2016;11(11):e0165703.
- Scheen A.J. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018;122(10):1439–1459.
- Tamargo J. Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action; Adverse Effects and Future Developments. Eur Cardiol. 2019;14(1):23–32.
- Анциферов М.Б.; Демидов Н.А.; Балберова М.А.; Лобанова О.В.; Мудрикова И.Г.; Гусенбекова Д.Г. Влияние ингибиторов натрий-глюкозного котранспортера 2-го типа дапаглифлозина на показатели общей смертности больных сахарным диабетом 2 типа (исследование CARDIA-MOS; Москва). Сахарный диабет. 2022;25(5):439–48.
Supplementary files
